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ABSTRACT
The term ‘undifferentiated connective tissue disease’ 
(UCTD) is generally used to describe clinical entities 
characterised by clinical and serological manifestations of 
systemic autoimmune diseases but not fulfilling the criteria 
for defined connective tissue diseases (CTDs). In this 
narrative review, we summarise the results of a systematic 
literature research, which was performed as part of the 
ERN ReCONNET project, aimed at evaluating existing 
clinical practice guidelines (CPGs) or recommendations.
No specific CPG on UCTD were found, potential areas 
of intervention are absence of a consensus definition 
of UCTD, need for specific monitoring and therapeutic 
protocols, stratification of UCTD based on the risk of 
developing a defined CTD and preventive measure for the 
future development of a more severe condition.
Patients feel uncertainty regarding the name of the disease 
and feel the need of a better education and understanding 
of these conditions and its possible changes over time.
INTRODUCTION
The term ‘undifferentiated connective 
tissue disease’ (UCTD) is generally used 
to describe clinical entities characterised 
by serological evidence of autoimmunity 
and by the occurrence of clinical symptoms 
often seen in association with systemic auto-
immune diseases (SADs), yet not fulfilling 
criteria for a specific SAD. Compared 
with other SADs, whose classifications are 
formally issued by rheumatological socie-
ties and periodically subject to discussion 
and revisions, the overall concept of UCTD 
may seem quite vague and prone to (mis)
interpretation. As such, clinicians may be 
tempted to classify early phases of other 
major SADs as UCTD. Not surprisingly, liter-
ature data show that up to 30% of UCTD may 
evolve into a definite ‘major’ SAD within few 
years from the diagnosis (all reviewed in1). 
The use of the term UCTD to describe an 
early phase of a major rheumatic disease 
and patient who temporarily lack sufficient 
features to meet other classification criteria 
was first proposed by LeRoy et al in 1980.2 
To best distinguish between UCTD at risk 
of evolution and stable UCTD, preliminary, 
yet often adopted, criteria for UCTD were 
proposed in 1999.3 Patients can be classified 
as UCTD if they fulfil the criteria as follows: 
Key messages
What is already known about this subject?
 ► Undifferentiated Connective Tissue Diseases (UCTD) 
is an orphan rheumatological condition often ob-
served in clinical practice.
 ► No guideline on UCTD diagnosis and management is 
widely accepted or routinely used.
What does this study add?
 ► An extensive literature search by the ERN 
ReCONNECT team could not identify any guideline or 
recommendation on UCTD.
How might this impact on clinical practice?
 ► Clinicians are concerned about the lack of a proper 
definition of UCTD, risk assessment as well as mon-
itoring and therapeutic strategies for patients with 
UCTD.
 ► Patients with UCTD may feel uncertainty regard-
ing UCTD diagnosis, therapeutic approach and 
prognosis.
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(1) signs and symptoms suggestive of a connective tissue 
disease (CTD), but not fulfilling criteria for a defined 
CTD, (2) positive antinuclear antibodies on two sepa-
rate measurements controls and (3) a disease duration 
of at least 3 years. These criteria strongly rely on the 
absence of other SADs, that is the inability to fulfil 
other classification criteria for major CTDs. During the 
last decade, classification criteria for other major SADs 
have been subject of extensive review in the attempt 
to make them more sensitive and capable of capturing 
early phases of CTDs.4–8 This process is actively ongoing 
and is likely to produce new sets of criteria in the very 
near future.9 It is clear that any new or revised criteria 
for SADs may affect our view of UCTD and change the 
‘label’ clinicians tag to patients with early autoimmune 
diseases. Still, it is unclear to what extent this improved 
knowledge will ultimately affect the clinical practice and 
the clinicians’ attitude at bedside. The current knowl-
edge on disease evolution in patients with UCTD and 
the factors that may influence the progression towards a 
definite SAD may be affected as well.10 These challenges 
are inflated considering the limited performance classi-
fication criteria may have when used as diagnostic tools 
in absence of proper diagnostic criteria.11 On the other 
hand, diagnostic criteria for UCTD may be difficult to 
develop in absence of clear-cut definitions and if too 
strict they may limit the ability to make a clinical diag-
nosis and preclude the patients a proper treatment and 
follow-up.
The present work tries to identify the current clinical 
practice guidelines (CPGs) in UCTD and the clinicians’ 
and patients’ unmet needs that come along with the diag-
nosis and changing definition of UCTD.
METHODS
Search for existing guidelines
We carried out a systematic search in PUBMED and 
EMBASE based on controlled terms (MeSH and Emtree, 
see below) and keywords of the disease and publica-
tion type (CPGs). Two independent reviewers (RT, 
CAS) screened all the retrieved articles applying the 
following inclusion criteria: UCTD (population) and 
CPGs on the area of diagnosis, monitoring and treat-
ment (study design). CPG were defined according to 
the Institute of Medicine 2011 definition (Clinical prac-
tice guidelines are statements that include recommendations 
intended to optimise patient care that are informed by a system-
atic review of evidence and an assessment of the benefits and 
harms of alternative care options). No language or year of 
publication restriction was applied.
The Disease Coordinators (DC) of the ERN- 
ReCONNET for UCTD (LB, MA) first performed 
a screening among papers included in the final list 
(systematic) based on Title and Abstract selected 
evidence-based medicine guidelines; second, they 
performed a hand search looking for existing guide-
lines in selected sites from national clinical societies and 
through multiple search engines (Google and Bing). 
Prespecified data extraction included author, year, 
area, clinical question coverage and AGREE II domains 
(Scope and Purpose; Stakeholder Involvement; Rigour 
of Development; Clarity of Presentation; Applicability; 
Editorial Independence. Data were planned to be 
reported descriptively by area (diagnosis, monitoring 
and management), to describe coverage and to inform 
the unmet need phase.
Medline (Pubmed) terms
(undifferentiated(All Fields) AND (‘connective 
tissue diseases’(MeSH Terms) OR (‘connective’(All 
Fields) AND ‘tissue’(All Fields) AND ‘diseases’(All 
Fields)) OR ‘connective tissue diseases’(All Fields) OR 
(‘connective’(All Fields) AND ‘tissue’(All Fields) AND 
‘disease’(All Fields)) OR ‘connective tissue disease’(All 
Fields))) AND (‘Practice Guideline’(Publication Type) 
OR ‘Practice Guidelines As Topic’(MeSH Terms) OR 
Practice Guideline(Publication Type) OR ‘Practice 
Guideline’(Text Word) OR ‘Practice Guidelines’(Text 
Word) OR ‘Guideline’(Publication Type) OR ‘Guide-
lines As Topic’(MeSH Terms) OR Guideline(Publi-
cation Type) OR ‘Guideline’(Text Word) OR ‘Guide-
lines’(Text Word) OR ‘Consensus Development Confer-
ence’(Publication Type) OR ‘Consensus Development 
Conferences As Topic’(MeSH Terms) OR ‘Consen-
sus’(MeSH Terms) OR ‘Consensus’(Text Word) OR 
‘Recommendation’(Text Word) OR ‘Recommenda-
tions’(Text Word) OR ‘Best Practice’(Text Word) OR 
‘Best Practices’(Text Word)).
Embase
(‘undifferentiated connective tissue disease’/exp OR 
(‘connective tissue disease’/exp OR ‘connective tissue 
disease’ OR ‘connective tissue diseases’ OR ‘connective 
tissue disorder’ AND undifferentiated)) AND (‘practice 
guideline’/exp OR ‘practice guideline’ OR ‘practice 
guidelines’/exp OR ‘practice guidelines’ OR ‘clinical 
practice guideline’/exp OR ‘clinical practice guide-
line’ OR ‘clinical practice guidelines’/exp OR ‘clinical 
practice guidelines’ OR 'clinical practice guidelines as 
topic'/exp OR ‘clinical practice guidelines as topic’ 
OR ‘guideline'/exp OR ‘guideline’ OR ‘guidelines’/
exp OR ‘guidelines’ OR ‘guidelines as topic’/exp OR 
‘guidelines as topic’ OR ‘consensus development’/exp 
OR ‘consensus development’ OR ‘consensus develop-
ment conference’/exp OR ‘consensus development 
conference’ OR ‘consensus development confer-
ences’/exp OR ‘consensus development conferences’ 
OR ‘consensus development conferences as topic’/
exp OR ‘consensus development conferences as topic’ 
OR ‘consensus’/exp OR ‘consensus’ OR ‘recommen-
dation’ OR ‘recommendations’) AND (embase)/lim 
NOT (medline)/lim
Identification of patient’s unmet needs
Patients and families referring to the ERN ReCONNET 
European Patients Advocacy Group (ePAG) as well as 
3Antunes M, et al. RMD Open 2019;4:e000786. doi:10.1136/rmdopen-2018-000786
Connective tissue diseases
caregivers have been deeply involved in the ERN activ-
ities and their personal views on UCTD unmet needs 
have been expressed during web conferences and 
meetings. The collected needs have been reviewed and 
rephrased by the patients’ representative and herein 
presented in a simplified and narrative form.
RESULTS
Identification of existing CPGs
Overall 108 articles were considered eligible for review 
after search in PUBMED and EMBASE. All of them were 
independently reviewed by LB and MA; both the reviewers 
agreed that none of the selected article contained suitable 
CPGs for further assessment. Similarly, the hand search via 
search engines and in selected websites did not yield any 
publication matching with inclusion criteria The overall 
result is that no CPG guideline on UCTD is currently 
publicly available.
Clinicians’ unmet needs
From literature and hand search, it is clear that several 
aspects of UCTD are still vague and as such we can iden-
tify several potential area of intervention or interest for 
the clinical practitioners.
1. The lack of CPGs on UCTD may reflect the lack of a 
consensus definition on UCTD. To date UCTD classi-
fication criteria are only provisional and may be con-
sidered outdated in light of the new SADs criteria that 
capture with increased sensitivity early or even preclin-
ical CTD in patients. We can thus identify the necessity 
to develop, refine and validate the definition of UCTD 
as a strong need.
2. In the absence of proper guidelines, it is unclear 
whether patients with UCTD with features resembling 
major SADs should be followed according to existing 
protocols and guidelines (ie, those reviewed in the oth-
er articles of the Supplement that come along with this 
work) or if specific guidelines should be developed.
3. It would be of interest to perform a proper stratifi-
cation of patients with UCTD in relation to the risk 
of  developing specific SADs. These patients could be 
generally labelled as ‘UCTD at risk for […]’ in relation 
to clinical, serological or other available data. Similar-
ly to what has beforehand been discussed (see point 
2), ad hoc guidelines could be developed for such pa-
tients or, alternatively, existing ones should be adapted 
and applied to them.
4. In the absence of rigorous prospective epidemio-
logical data, it is unclear to what extent the early in-
troduction or the use of drugs developed for other 
indications or commonly prescribed in rheumatol-
ogy clinical practice may be useful for patients with 
UCTD. The impact of such therapeutic approach on 
the natural history of UCTD is unclear. Specific (in-
ter)national registries for UCTD may facilitate collec-
tion of these data.12
Patients’ unmet needs
This paragraph intends to highlight the unmet needs of 
the Undifferentiated Connective Tissue Disease Euro-
pean community. The content of this paragraph has been 
realised by the ERN ReCONNET ePAG that carefully but 
relentlessly collected the voices and the points of view of 
the whole European community of the disease they repre-
sent. The rarity of the disease and the scarcity of patient 
organisations made this work harder than expected.
Patients feel uncertainty regarding the name of the 
disease; the word ‘undifferentiated’ makes them feel as 
if they do not have a proper disease, but rather one that 
only in the future will become a recognised disease. This 
feeling has a high impact on their health related quality of 
life. Patients may feel neglected as the mere presence of 
antinuclear antibody titres do not seem to justify the neces-
sity of consistent diagnostic and follow-ups, which should 
be better explained. The (low) risk percentage of devel-
oping another SAD and its consequences should be better 
described, as well as the bigger chance of not developing 
another SAD. Patients also refer to the lack of informa-
tion on the disease and report the lack of involvement by 
healthcare providers in producing the existing documents, 
maybe due to the scarcity of patients’ groups. The lack of 
CPGs for UCTD seems to substantiate this complaint.
CONCLUSION
The current lack of available CPGs clearly shows that UCTD 
is somehow neglected as compared with other major SADs. 
Despite the possibility that some patients with UCTD may 
indeed harbour the possibility to progress towards early 
and definite forms of other CTDs, there is no consensus on 
the optimal management of these patients. In the absence 
of clear-cut epidemiological studies and of a thorough risk 
assessment, individual experience still guides the clinician’s 
choice. As such, patients with UCTD are left within an area 
of uncertainty despite the generic reassurance that their 
disease is somehow ‘milder’ compared with defined SADs. 
This attitude is clearly a source of discomfort as patients 
and relatives feel disturbing an uncertain situation that may 
leave more questions than answers (What do I exactly have? 
What will happen to me? How will my disease develop?). 
The uncertainty regarding UCTD diagnosis, therapeutic 
approach and prognosis may influence patients’ coping 
strategies, discourage a thorough and systematic follow-up 
and assessment which may have potential drawbacks on the 
early identification of cases progressing towards definite 
SADs or development of severe complications. Patients may 
feel a reduced trust on healthcare providers, which has a 
direct effect on outcomes of care.13 Consequently, focused 
efforts are clearly needed to integrate the specialist’s expe-
rience with patients’ needs and expectations to foster the 
development of formal UCTD CPGs.
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